RWC Asset Management LLP Acquires Shares of 8,326 Zai Lab Limited (NASDAQ:ZLAB)

RWC Asset Management LLP acquired a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,326 shares of the company’s stock, valued at approximately $228,000.

Other large investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Zai Lab by 68.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,371 shares of the company’s stock worth $33,000 after purchasing an additional 557 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Zai Lab by 58.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,896 shares of the company’s stock worth $46,000 after purchasing an additional 700 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Zai Lab in the 4th quarter worth about $116,000. Shell Asset Management Co. raised its position in Zai Lab by 8.3% in the 3rd quarter. Shell Asset Management Co. now owns 8,475 shares of the company’s stock worth $206,000 after buying an additional 652 shares during the last quarter. Finally, Triatomic Management LP raised its position in Zai Lab by 30.8% in the 3rd quarter. Triatomic Management LP now owns 17,000 shares of the company’s stock worth $413,000 after buying an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Transactions at Zai Lab

In other news, insider Joshua L. Smiley sold 1,988 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the sale, the insider now directly owns 28,684 shares of the company’s stock, valued at approximately $449,478.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the sale, the insider now owns 28,684 shares in the company, valued at approximately $449,478.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rafael Amado sold 2,544 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $18.86, for a total value of $47,979.84. Following the sale, the insider now owns 20,093 shares in the company, valued at approximately $378,953.98. The disclosure for this sale can be found here. Insiders have sold 12,568 shares of company stock valued at $208,508 in the last ninety days. Corporate insiders own 5.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Friday, January 12th. Citigroup decreased their target price on Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zai Lab has a consensus rating of “Buy” and a consensus target price of $64.22.

Zai Lab Stock Up 1.1 %

NASDAQ ZLAB traded up $0.17 during trading hours on Friday, reaching $15.91. The company’s stock had a trading volume of 364,581 shares, compared to its average volume of 470,952. The firm’s 50-day moving average price is $17.45 and its 200-day moving average price is $22.58. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $39.50. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -4.61 and a beta of 1.10.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.11). Zai Lab had a negative return on equity of 37.07% and a negative net margin of 125.46%. The business had revenue of $65.83 million during the quarter, compared to analysts’ expectations of $70.41 million. Equities research analysts anticipate that Zai Lab Limited will post -3.27 EPS for the current fiscal year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.